USFDA concludes inspection at Natco Pharma’s API manufacturing plant in Manali
The said inspection was conducted from November 17, 2025 to November 21, 2025
The U.S. Food and Drug Administration (USFDA) has concluded inspection at Natco Pharma’s Active Pharmaceutical Ingredients (API) manufacturing plant located in Manali, Chennai. The said inspection was conducted from November 17, 2025 to November 21, 2025.
On conclusion of the inspection, the company received seven observations in the Form-483. The company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
